Datar Cancer Genetics Unveils Exacta AI: A Revolutionary AI-Driven Cancer Treatment Platform

Metropolis Healthcare Partners with Roche to Launch Self-Sampling HPV DNA Test for Cervical Cancer Screening in India

Union Budget 2025: Full Exemption from Basic Customs Duty (BCD) for 36 Lifesaving Drugs

Dr. Jitendra Singh Inaugurates Centre for Advanced Genomics & Precision Medicine at AIIMS Jammu

Union Budget 2025-26: Key Healthcare Measures for Cancer Care and Access to Life-Saving Drugs

FDA Approves Roche’s PATHWAY HER2 Test for Identifying HER2-Ultralow Breast Cancer Patients Eligible for ENHERTU

Bristol Myers Squibb’s Breyanzi® Receives CHMP Recommendation for Relapsed or Refractory Follicular Lymphoma in the EU

NHS to Offer Groundbreaking Gene Therapy for Sickle Cell Disease

Quibim Secures $50M Series A to Advance AI-Powered Imaging for Precision Medicine

Apollo Hospitals Unveils Advanced Oncology Facility in Chennai

Beckman Coulter’s Alzheimer’s Blood Test Receives FDA Breakthrough Device Designation

ANGLE Announces Breakthrough Dual CTC-DNA and ctDNA Analysis with Illumina’s NGS Solution

Diatech Pharmacogenetics and Merck Expand Collaboration to Enhance RAS Biomarker Testing in MEA Region

DCG Unveils AI-Powered Video-Reporting for Personalized Chemotherapy Selection

FDA Approves Monthly Maintenance Dosing for LEQEMBI® in Alzheimer’s Treatment

Home
/
update
/
details

Beyond Genes: Harnessing Epigenetics for Early Cancer Identification

NextEdge Admin

18 Nov 2023

3 min 47 sec

Epigenetics plays a critical role in the early detection of cancer by providing molecular signatures that can indicate the presence of abnormal cellular processes associated with cancer development. Various epigenetic changes, such as DNA methylation, histone modifications, and non-coding RNA expression, can serve as biomarkers for cancer detection. Here’s how epigenetics contributes to the early detection of cancer:

DNA Methylation:

Aberrant DNA methylation patterns are commonly observed in cancer cells. Promoter hypermethylation of tumor suppressor genes and hypomethylation of oncogenes are frequent events in cancer. These methylation changes can be detected in circulating free DNA (cfDNA) in the blood, known as liquid biopsy, providing a minimally invasive method for early cancer detection.

Histone Modifications:

Changes in histone modifications, such as acetylation and methylation, can influence chromatin structure and gene expression. Altered histone modification patterns are associated with cancer, and profiling these changes can help identify epigenetic signatures indicative of early-stage disease.

MicroRNA Expression:

MicroRNAs (miRNAs) are small non-coding RNAs that play a role in post-transcriptional gene regulation. Dysregulation of miRNA expression is associated with cancer development. Profiling miRNA expression patterns in tissues or biofluids can provide information about the presence of cancer and its specific type.

Long Non-Coding RNAs (lncRNAs):

Long non-coding RNAs are another class of non-coding RNAs that have been implicated in cancer. They can regulate gene expression and contribute to oncogenesis. Aberrant expression of specific lncRNAs can serve as diagnostic markers for various cancers.

Circulating Tumor DNA (ctDNA):

The presence of ctDNA in the bloodstream, which includes DNA shed by cancer cells, can be analyzed for epigenetic alterations. Detection of cancer-specific DNA methylation patterns in ctDNA allows for the non-invasive monitoring of cancer progression and early detection of recurrence.

Epigenetic Signatures in Tissues:

Epigenetic profiling of cancer tissues, using techniques such as DNA methylation arrays or next- generation sequencing, can reveal unique epigenetic signatures associated with different cancer types. These signatures can be used for early cancer diagnosis and classification.

Screening and Surveillance:

Epigenetic markers can be integrated into cancer screening and surveillance programs. For example, certain DNA methylation markers have been explored for use in colorectal cancer screening, helping to identify individuals at higher risk who may need further diagnostic evaluation.

Related Tags

Epigenetics

Cancer Identification

Proteomics in the Quest for Biomarkers

From Complexity to Accessibility: Transforming SMA Diagnosis with MLPA-NGS Technology

Top Reviews

No reviews yet

Beyond Genes: Harnessing Epigenetics for Early Cancer Identification

NextEdge Admin

18 Nov 2023

3 min 47 sec

DNA Methylation:

Aberrant DNA methylation patterns are commonly observed in cancer cells. Promoter hypermethylation of tumor suppressor genes and hypomethylation of oncogenes are frequent events in cancer. These methylation changes can be detected in circulating free DNA (cfDNA) in the blood, known as liquid biopsy, providing a minimally invasive method for early cancer detection.

Histone Modifications:

Changes in histone modifications, such as acetylation and methylation, can influence chromatin structure and gene expression. Altered histone modification patterns are associated with cancer, and profiling these changes can help identify epigenetic signatures indicative of early-stage disease.

MicroRNA Expression:

MicroRNAs (miRNAs) are small non-coding RNAs that play a role in post-transcriptional gene regulation. Dysregulation of miRNA expression is associated with cancer development. Profiling miRNA expression patterns in tissues or biofluids can provide information about the presence of cancer and its specific type.

Long Non-Coding RNAs (lncRNAs):

Long non-coding RNAs are another class of non-coding RNAs that have been implicated in cancer. They can regulate gene expression and contribute to oncogenesis. Aberrant expression of specific lncRNAs can serve as diagnostic markers for various cancers.

Circulating Tumor DNA (ctDNA):

The presence of ctDNA in the bloodstream, which includes DNA shed by cancer cells, can be analyzed for epigenetic alterations. Detection of cancer-specific DNA methylation patterns in ctDNA allows for the non-invasive monitoring of cancer progression and early detection of recurrence.

Epigenetic Signatures in Tissues:

Epigenetic profiling of cancer tissues, using techniques such as DNA methylation arrays or next- generation sequencing, can reveal unique epigenetic signatures associated with different cancer types. These signatures can be used for early cancer diagnosis and classification.

Screening and Surveillance:

Epigenetic markers can be integrated into cancer screening and surveillance programs. For example, certain DNA methylation markers have been explored for use in colorectal cancer screening, helping to identify individuals at higher risk who may need further diagnostic evaluation.